Market Closed -
Nasdaq
04:30:01 2024-03-28 pm EDT
5-day change
1st Jan Change
10.59
USD
+0.67%
+6.75%
-11.75%
Presentation Operator MessageOperator (Operator)Good day, and welcome to the CareDx, Inc. Seco...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors
Mar. 11
CI
Transcript : CareDx, Inc, Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Earnings Flash (CDNA) CAREDX Reports Q4 Revenue $65.6M, vs. Street Est of $64.1M
Feb. 28
MT
CareDx, Inc Provides Revenue Guidance for the Full Year of 2024
Feb. 28
CI
CareDx, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 28
CI
CareDx, Inc Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring
Feb. 21
CI
Natera Awarded About $96.3 Million in Patent Infringement Case Against CareDx
Jan. 29
MT
Transcript : CareDx, Inc - Special Call
Jan. 11
CareDx's Preliminary Q4, 2023 Revenue Top Consensus
Jan. 09
MT
Tranche Update on CareDx, Inc's Equity Buyback Plan announced on December 6, 2022.
Jan. 09
CI
CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023
Jan. 09
CI
CareDx, Inc Revises Revenue Guidance for the Full Year Ended December 31, 2023
Jan. 09
CI
Natera Says Delaware Court Denies CareDx's Motion for Summary Judgment on Two Patents, Lawsuit to Proceed to Trial
Dec. 11
MT
Sector Update: Health Care Stocks Higher Late Afternoon
Dec. 11
MT
Sector Update: Health Care
Dec. 11
MT
Natera Says Delaware Court Denies CareDx's Motion for Summary Judgment on Two Patents, Lawsuit to Proceed to Trial
Dec. 11
MT
Transcript : CareDx, Inc - Special Call
Nov. 15
North American Morning Briefing : Investors Weigh -2-
Nov. 10
DJ
Stephens Upgrades CareDx to Overweight From Equalweight, Price Target is $10
Nov. 09
MT
Wall Street Set to Open Higher Thursday as Jobless Claims Fall, Ahead of Powell Speech
Nov. 09
MT
CareDx Surges 14% Premarket Thursday After Reporting Q3 Revenue Above Expectations, Lifting Full-Year Sales Guidance
Nov. 09
MT
Transcript : CareDx, Inc, Q3 2023 Earnings Call, Nov 08, 2023
Nov. 08
Tranche Update on CareDx, Inc's Equity Buyback Plan announced on December 6, 2022.
Nov. 08
CI
CareDx, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 08
CI
Earnings Flash (CDNA) CAREDX Reports Q3 Revenue $67.2M, vs. Street Est of $53.1M
Nov. 08
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
More about the company
Last Close Price
10.59
USD
Average target price
12.4
USD
Spread / Average Target
+17.09%
Consensus
1st Jan change
Capi.
-11.75% 548M -6.65% 12.54B +82.29% 4.14B -14.23% 2.34B -23.73% 2.51B -19.45% 1.66B +32.37% 1.15B +7.42% 840M -34.49% 466M +42.88% 277M
Bio Diagnostics & Testing
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1